Compare ATS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | ZLAB |
|---|---|---|
| Founded | 1978 | 2013 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2007 | 2017 |
| Metric | ATS | ZLAB |
|---|---|---|
| Price | $19.45 | $25.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $35.00 | ★ $49.60 |
| AVG Volume (30 Days) | 216.1K | ★ 1.2M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $17.99 | $9.75 |
| Revenue Next Year | $4.52 | $26.03 |
| P/E Ratio | $222.92 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $18.41 | $15.96 |
| 52 Week High | $35.82 | $34.72 |
| Indicator | ATS | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 55.00 |
| Support Level | $19.14 | $24.81 |
| Resistance Level | $20.11 | $27.08 |
| Average True Range (ATR) | 0.50 | 0.76 |
| MACD | 0.29 | -0.29 |
| Stochastic Oscillator | 53.24 | 22.12 |
ATS Corp is engaged in planning, designing, building, commissioning and servicing automated manufacturing systems - including automation products and test solutions - for a broadly diversified base of customers. The company focuses in five key markets: life sciences, food & beverage, transportation, consumer products and energy. The Company's operations are reported as one operating segment, Automation Systems, which plans, allocates resources, builds capabilities and implements practices on a world-wide basis. The company has presence in Canada, United States, Germany, Italy, Other Europe, and Other.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.